Oncogenic driver mutations commonly found in NSCLC include EGFR, ALK, DDR1, Kras and Notch, each contributing to the therapeutic outcome/resistance observed when administered conventional and/or targeted therapy [2,125,126]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.